[go: up one dir, main page]

CL2018001151A1 - Suspensión acuosa para administración oral y método para su preparación - Google Patents

Suspensión acuosa para administración oral y método para su preparación

Info

Publication number
CL2018001151A1
CL2018001151A1 CL2018001151A CL2018001151A CL2018001151A1 CL 2018001151 A1 CL2018001151 A1 CL 2018001151A1 CL 2018001151 A CL2018001151 A CL 2018001151A CL 2018001151 A CL2018001151 A CL 2018001151A CL 2018001151 A1 CL2018001151 A1 CL 2018001151A1
Authority
CL
Chile
Prior art keywords
preparation
oral administration
aqueous suspension
givinostat
oral
Prior art date
Application number
CL2018001151A
Other languages
English (en)
Inventor
Giuseppe Colombo
Roberta Artico
Paolo Mascagni
Maria Valmen Monzani
Silvia Puccianti
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of CL2018001151A1 publication Critical patent/CL2018001151A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULACIONES LÍQUIDAS ORALES FÍSICA Y QUÍMICAMENTE ESTABLES DE GIVINOSTAT (DIETIL-[6- (4-HIDROXICARBAMOIL-FENILCARBONILOXIETIL)-NAFTALEN-2-IL-METIL]-CLORURO AMÓNICO) JUNTO CON MÉTODOS PARA LA PREPARACIÓN DE LAS MISMAS. TALES FORMULACIONES ORALES SON EN FORMA DE SUSPENSIONES ACUOSAS Y CONTIENEN GIVINOSTAT Y/O SALES ACEPTABLES PARA USO FARMACÉUTICO Y/O DERIVADAS DE LAS MISMAS, POR LO MENOS UN AGENTE HUMECTANTE Y/O POR LO MENOS UN AGENTE QUE IMPARTE DENSIDAD. SON ADECUADAS PARA LA ADMINISTRACIÓN ORAL PARA LA ACCIÓN TERAPÉUTICA SISTÉMICA.
CL2018001151A 2015-11-03 2018-04-30 Suspensión acuosa para administración oral y método para su preparación CL2018001151A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUB2015A005193A ITUB20155193A1 (it) 2015-11-03 2015-11-03 Sospensioni orali di Givinostat fisicamente e chimicamente stabili

Publications (1)

Publication Number Publication Date
CL2018001151A1 true CL2018001151A1 (es) 2018-12-07

Family

ID=55410062

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001151A CL2018001151A1 (es) 2015-11-03 2018-04-30 Suspensión acuosa para administración oral y método para su preparación

Country Status (33)

Country Link
US (1) US10688047B2 (es)
EP (1) EP3370697B1 (es)
JP (1) JP6800970B2 (es)
KR (1) KR102603894B1 (es)
CN (2) CN108366956B (es)
AR (1) AR106559A1 (es)
AU (1) AU2016349169B2 (es)
BR (1) BR122024001653A2 (es)
CA (1) CA3002755C (es)
CL (1) CL2018001151A1 (es)
CO (1) CO2018003971A2 (es)
CY (1) CY1124092T1 (es)
DK (1) DK3370697T3 (es)
ES (1) ES2870201T3 (es)
FI (1) FIC20250035I1 (es)
FR (1) FR25C1051I1 (es)
HR (1) HRP20210747T1 (es)
HU (2) HUE054123T2 (es)
IL (1) IL258608B (es)
IT (1) ITUB20155193A1 (es)
LT (2) LT3370697T (es)
MX (1) MX380361B (es)
NO (1) NO2025053I1 (es)
NZ (1) NZ741467A (es)
PE (1) PE20181369A1 (es)
PL (1) PL3370697T3 (es)
PT (1) PT3370697T (es)
RS (1) RS61694B1 (es)
RU (1) RU2721396C2 (es)
SI (1) SI3370697T1 (es)
SM (1) SMT202100161T1 (es)
TW (1) TWI727983B (es)
WO (1) WO2017077436A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190216818A1 (en) 2016-07-15 2019-07-18 Viracta Therapeutics, Inc. Histone deacetylase inhibitors for use in immunotherapy
IT201900003281A1 (it) * 2019-03-06 2020-09-06 Chemi Spa Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza
CN114206447A (zh) 2019-05-31 2022-03-18 维拉克塔附属公司 用组蛋白脱乙酰基酶抑制剂治疗病毒相关的癌症的方法
WO2022088037A1 (zh) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Sirtinol在制备预防和治疗冠状病毒的药物中的应用
CN114306311A (zh) * 2022-01-14 2022-04-12 同济大学 组蛋白去乙酰化酶抑制剂在制备治疗心脏病的药物中的应用
CN116173003A (zh) * 2023-02-24 2023-05-30 山西医科大学 药物吉维司他在治疗阿尔茨海默病中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169150A (en) * 1975-11-12 1979-09-25 Teijin Limited Benzodiazepine derivatives and pharmaceutical compositions containing said derivatives
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
NZ525439A (en) 2000-09-29 2004-11-26 Topotarget Uk Ltd Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
CA2470912A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Pharmaceutical suspension for oral administration
KR20040090978A (ko) 2002-03-13 2004-10-27 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의 설포닐-유도체
ITMI20030063A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
JP4243628B2 (ja) 2003-04-07 2009-03-25 ファーマサイクリックス，インコーポレイティド 治療剤としてのヒドロキサメート
ATE353319T1 (de) 2003-08-20 2007-02-15 Axys Pharm Inc Acetylenderivate als inhibitoren von histondeacetylase
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
KR101261305B1 (ko) 2004-07-28 2013-05-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
WO2006018814A2 (en) * 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Oral liquid suspensions of metaxalone
WO2007135362A2 (en) * 2006-05-19 2007-11-29 Norbrook Laboratories Limited Stable aqueous suspension having palatable taste
SG174772A1 (en) 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
CN102802631A (zh) * 2009-10-30 2012-11-28 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
US20110245154A1 (en) * 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
TW201245115A (en) * 2011-01-24 2012-11-16 Chdi Foundation Inc Histone deacetylase inhibitors and compositions and methods of use thereof
MX349767B (es) * 2012-02-03 2017-08-11 Italfarmaco Spa Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
WO2014165226A2 (en) * 2013-03-12 2014-10-09 Synedgen, Inc. Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar
WO2014159224A1 (en) * 2013-03-14 2014-10-02 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2015086738A2 (en) 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine

Also Published As

Publication number Publication date
MX380361B (es) 2025-03-12
AU2016349169A1 (en) 2018-05-17
PE20181369A1 (es) 2018-08-27
JP2019501116A (ja) 2019-01-17
DK3370697T3 (da) 2021-04-26
BR122024001653A2 (pt) 2024-03-05
CN113368044B (zh) 2023-06-02
ES2870201T3 (es) 2021-10-26
RS61694B1 (sr) 2021-05-31
MX2018004505A (es) 2018-09-12
CO2018003971A2 (es) 2018-07-19
ITUB20155193A1 (it) 2017-05-03
IL258608B (en) 2022-06-01
KR20180082468A (ko) 2018-07-18
CA3002755A1 (en) 2017-05-11
LTPA2025540I1 (es) 2025-12-29
CN108366956B (zh) 2021-09-10
BR112018008870A8 (pt) 2019-02-26
NZ741467A (en) 2021-07-30
US20180311160A1 (en) 2018-11-01
KR102603894B1 (ko) 2023-11-20
AU2016349169B2 (en) 2021-11-11
PT3370697T (pt) 2021-04-06
SI3370697T1 (sl) 2021-04-30
EP3370697A1 (en) 2018-09-12
RU2721396C2 (ru) 2020-05-19
NO2025053I1 (no) 2025-12-05
JP6800970B2 (ja) 2020-12-16
TWI727983B (zh) 2021-05-21
FIC20250035I1 (fi) 2025-12-05
CA3002755C (en) 2022-10-18
SMT202100161T1 (it) 2021-05-07
TW201722401A (zh) 2017-07-01
CN108366956A (zh) 2018-08-03
BR112018008870A2 (pt) 2018-11-06
US10688047B2 (en) 2020-06-23
FR25C1051I1 (fr) 2026-01-16
HUS2500049I1 (hu) 2025-12-28
HUE054123T2 (hu) 2021-08-30
WO2017077436A1 (en) 2017-05-11
HRP20210747T1 (hr) 2021-06-25
EP3370697B1 (en) 2021-02-17
HK1254811A1 (en) 2019-07-26
PL3370697T3 (pl) 2021-07-12
CY1124092T1 (el) 2022-05-27
RU2018120170A (ru) 2019-12-05
RU2018120170A3 (es) 2019-12-05
LT3370697T (lt) 2021-06-10
CN113368044A (zh) 2021-09-10
AR106559A1 (es) 2018-01-24
IL258608A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
CL2018001151A1 (es) Suspensión acuosa para administración oral y método para su preparación
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
PL3896064T3 (pl) Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego
CY1122695T1 (el) Αλας toy omecamtiv mecarbil και διαδικασια για την παρασκευη αλατος
HUE055838T2 (hu) Amfifil poliszacharid-származékok és azokat tartalmazó készítmények
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
HUE049341T2 (hu) Szubsztituált indazolok, eljárás ezek elõállítására, ezeket tartalmazó gyógyszerkészítmények, valamint ezek alkalmazása gyógyszerkészítmények elõállítására
MX378273B (es) Compuestos activos hacia bromodominios.
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
IL280827A (en) Integrin alpha 4 antagonists and compositions comprising same for use in treating ocular conditions
CL2015002835A1 (es) Nuevos derivados de piridina
BR112017004393A2 (pt) formulações de anticorpo
HUE071358T2 (hu) Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
CL2017003437A1 (es) Formulación solida oral que contiene irinotecán y método de preparación de la misma
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
AR104185A1 (es) Formulaciones farmacéuticas
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
MX383682B (es) Tratamiento para cancer de mama usando una combinación de una formulación liposomal catiónica de taxano, una formulación no liposomal de taxano y un agente activo adicional.
PH12018502139A1 (en) Phosphaplatin liquid formulations
HUE058886T2 (hu) Safinamidot tartalmazó gyógyászati készítmények
TH158486A (th) องค์ประกอบของยาปฏิชีวนะเซฟโทโลเซน
Lapadusi 3D Face Reconstruction, Sculptural Modelling in Forensics
AR105601A1 (es) Formulaciones y usos para suministro de micropartículas de metaloporfirinas